About half of people with gout don't have treatments that work. Meet the new gout drugs racing through trials to reach them.

The only TIL therapy approved so far is Amtagvi for melanoma. Here are six companies with promising TIL therapies in the ...

Roche's AXELIOS 1 enters next generation DNA sequencing. Can it or rivals unseat Illumina's long-standing market dominance?

With 10 cases in 2025, Guinea worm could be the second disease ever eradicated. Here is what makes disease eradication ...

So far, the visible strategy around bronchiectasis has been managing the problems it creates — mucus retention, repeated infections, airway inflammation, and exacerbations. Airway clearance, ...

For a long time, neurological drug development has largely focused on the cells that ultimately die or malfunction. Alzheimer’s researchers chased amyloid and tau. Parkinson’s drug development ...

RAS mutations are among the most common drivers in cancer, particularly in pancreatic, colorectal, and lung tumors. Despite that, directly targeting RAS proteins proved extremely difficult for years, ...

Unlike traditional drugs that bind directly to a protein’s active site, allosteric modulators act at separate regulatory sites, allowing them to fine-tune biological activity and act more like a ...

Bristol Myers Squibb is experiencing what many would describe as a pivotal moment as it attempts to balance the strength of its established portfolio with the growing pressure of upcoming patent ...

Candel Therapeutics is focused on the development of off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight ...

More than 1.9 million new colorectal cancer cases were diagnosed in 2022, making it the third most common cancer type globally, and it was linked to more than 900,000 deaths that year. This makes ...

The healthcare funding landscape was not particularly kind to the U.K. in 2025. Following Merck pulling out of its $1 billion expansion plans in London, it was evident that life science investments in ...